Health
Bharat Biotechs Covaxin succeeds in challenge trials on Rhesus monkeys – Business Standard
The results showed protective efficacacy, increasing Sars-CoV-2 specific IgG and neutralising antibodies reducing the replication of the virus in the nasal cavity, throat and lung tissues of monkey
Hyderabad-based Bharat Biotech has released the data from the animal trials of its vaccine candidate, which showed that Covaxin was able to generate ‘robust immune responses’.
The firm said that the vaccine prevented infection and disease in the primates upon high amounts of exposure to live virus Sars-CoV-2. This is called a challenge trial where a participant is exposed deliberately to the pathogen after being given the vaccine shot.
The company tweeted “Bharat Biotech proudly announces th…
-
Noosa News16 hours agoNRL legend Trevor Gillmeister charged with assaulting police officer at Brisbane pub
-
Business19 hours agoMacquarie tips more than 20% upside for this ASX mining stock
-
Noosa News17 hours agoSchools ban e-bikes | Noosa Today
-
General16 hours agoCatholic Education Tasmania to close six schools, with three others partially closed, due to coloured sand recall